|Day Low/High||281.56 / 284.56|
|52 Wk Low/High||208.34 / 305.45|
Value stocks will extend their outperformance over growth stocks that began last year.
Thermo Fisher Scientific and IHS Markit are both breaking out of tight patterns.
We strongly recommend members avoid any temptation to trade around political events.
Back from my meetings to find the S&P 500 Index basically traded in a 2-3 point range over the last four hours, which is a statistically improbable event! Highs were made early in the day when I issued my Trade of the Week (short SPDR S&P 500 ETF ...
The highly elusive Cleveland Research is putting the screws to Fitbit.
One firm's channel checks hit some of the market's biggest giants -- meaning investors should keep an eye on the Midwest.
A handful of financial firms are establishing their roots in the Midwest, but that doesn't mean the boys in the Big Apple don't use the resources coming from Cleveland.
Thermo Fisher is looking bullish, while Blue Buffalo goes the other way.
Smaller, independent equity research firms are starting to cause bigger waves in the marketplace, but is the information really that valuable?
The recent pullback will be a pause that refreshes, positioning the company for its next leg up.
Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.
Thermo Fisher's shares are trading higher on Friday after the company announced it would buy FEI for approximately $4.2 billion.
U.S. stocks held slight gains at midday on Friday as investors looked toward a speech from Federal Reserve Chair Janet Yellen this afternoon.
Thermo Fisher plans to buy microscope maker FEI for about $4.2 billion and Jim Cramer says FEI shareholders should take the money and run.
Also, Thermo Fisher annouces an acquisition as takeover talks boost Valeant shares.
As Valeant launches allegations of improper financial reporting at its former CFO, experts say it ought to take a close look at the composition of its audit committee.
We would anticipate a breakout to upside; a decline below $130 would turn us neutral on TMO.
Stanley Black & Decker and Thermo Fisher provide an unfortunate lesson.
While we don't want to alarm readers, we are increasingly concerned around the market's movement heading into year-end.
The management recently gave a very upbeat presentation.
Traders can finally shift focus from macro headlines in Greece and China as earnings are in full swing with hundreds of companies expected to report quarterly results.
Traders can finally shift focus from macro headlines in Greece and China as earnings go into full swing next week with hundreds of companies expected to report quarterly results.
TMO is a buy after a strong close above the wedge downtrend line.